eprintid: 1454494 rev_number: 53 eprint_status: archive userid: 608 dir: disk0/01/45/44/94 datestamp: 2014-11-06 01:41:11 lastmod: 2021-12-13 02:28:14 status_changed: 2015-06-08 11:05:52 type: article metadata_visibility: show item_issues_count: 0 creators_name: Lecour, S creators_name: Bøtker, HE creators_name: Condorelli, G creators_name: Davidson, SM creators_name: Garcia-Dorado, D creators_name: Engel, FB creators_name: Ferdinandy, P creators_name: Heusch, G creators_name: Madonna, R creators_name: Ovize, M creators_name: Ruiz-Meana, M creators_name: Schulz, R creators_name: Sluijter, JP creators_name: Van Laake, LW creators_name: Yellon, DM creators_name: Hausenloy, DJ title: ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies ispublished: pub divisions: UCL divisions: B02 divisions: D14 divisions: GA2 keywords: Animal models, Cardioprotection, Ischaemia, Myocardial infarction, Reperfusion note: © The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com abstract: Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of Cardiology Working Group Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes. date: 2014-10-24 official_url: http://dx.doi.org/10.1093/cvr/cvu225 vfaculties: VFPHS oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green article_type: review article_type_text: REVIEW verified: verified_manual elements_source: PubMed elements_id: 990042 doi: 10.1093/cvr/cvu225 pii: cvu225 language_elements: ENG lyricists_name: Davidson, Sean lyricists_name: Hausenloy, Derek lyricists_name: Yellon, Derek lyricists_id: SDAVI13 lyricists_id: DHAUS05 lyricists_id: DMYEL52 full_text_status: public publication: Cardiovasc Res volume: 104 number: 3 pagerange: 399-411 issn: 0008-6363 citation: Lecour, S; Bøtker, HE; Condorelli, G; Davidson, SM; Garcia-Dorado, D; Engel, FB; Ferdinandy, P; ... Hausenloy, DJ; + view all <#> Lecour, S; Bøtker, HE; Condorelli, G; Davidson, SM; Garcia-Dorado, D; Engel, FB; Ferdinandy, P; Heusch, G; Madonna, R; Ovize, M; Ruiz-Meana, M; Schulz, R; Sluijter, JP; Van Laake, LW; Yellon, DM; Hausenloy, DJ; - view fewer <#> (2014) ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies. [Review]. Cardiovasc Res , 104 (3) pp. 399-411. 10.1093/cvr/cvu225 <https://doi.org/10.1093/cvr%2Fcvu225>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/1454494/2/399.full.pdf